CA2157671A1 - Medicament for treating or preventing cerebrovascular diseases - Google Patents

Medicament for treating or preventing cerebrovascular diseases

Info

Publication number
CA2157671A1
CA2157671A1 CA002157671A CA2157671A CA2157671A1 CA 2157671 A1 CA2157671 A1 CA 2157671A1 CA 002157671 A CA002157671 A CA 002157671A CA 2157671 A CA2157671 A CA 2157671A CA 2157671 A1 CA2157671 A1 CA 2157671A1
Authority
CA
Canada
Prior art keywords
alkyl
imidazol
hydrogen
lower alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002157671A
Other languages
English (en)
French (fr)
Inventor
Kiyotaka Katsuta
Hiroyuki Takamatsu
Yoshiko Ueda
Hajime Nakan-Ishi
Keizo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939304701A external-priority patent/GB9304701D0/en
Priority claimed from GB939320882A external-priority patent/GB9320882D0/en
Application filed by Individual filed Critical Individual
Publication of CA2157671A1 publication Critical patent/CA2157671A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002157671A 1993-03-08 1994-02-16 Medicament for treating or preventing cerebrovascular diseases Abandoned CA2157671A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939304701A GB9304701D0 (en) 1993-03-08 1993-03-08 New use
GB93.04701.7 1993-03-08
GB93.20882.5 1993-10-11
GB939320882A GB9320882D0 (en) 1993-10-11 1993-10-11 New use

Publications (1)

Publication Number Publication Date
CA2157671A1 true CA2157671A1 (en) 1994-09-15

Family

ID=26302552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002157671A Abandoned CA2157671A1 (en) 1993-03-08 1994-02-16 Medicament for treating or preventing cerebrovascular diseases

Country Status (10)

Country Link
US (3) US5607938A (enExample)
EP (1) EP0688216A1 (enExample)
JP (1) JPH08507514A (enExample)
KR (1) KR960700711A (enExample)
CN (1) CN1118990A (enExample)
AU (1) AU683447B2 (enExample)
CA (1) CA2157671A1 (enExample)
HU (1) HUT68293A (enExample)
TW (1) TW305760B (enExample)
WO (1) WO1994020102A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005367A2 (en) * 1994-08-16 1996-02-22 Beloit Technologies, Inc. Hydrostatic self-loading controlled deflection roll
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US7592344B2 (en) * 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
RU2340342C2 (ru) * 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CN103755708B (zh) * 2013-12-31 2016-09-07 浙江大学 一种吲哚或吡咯并嘧啶衍生物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22672A (en) * 1984-01-25 1988-11-14 Glaxo Group Ltd Imidazolylmethyltetrahydrocarbazolone derivatives, composition and method of use thereof
AU583343B2 (en) * 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4985437A (en) * 1986-12-17 1991-01-15 Glaxo Group Limited Medicaments
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
IE60991B1 (en) * 1986-12-17 1994-09-07 Glaxo Group Ltd Use of ketone derivatives in the treatment of cognitive disorders
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
US5173493A (en) * 1988-09-27 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Pyridoindole derivatives and processes for preparation thereof
ATE137501T1 (de) * 1989-07-03 1996-05-15 Yoshitomi Pharmaceutical Benzazin-verbindungen und deren pharmazeutische verwendungen
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders

Also Published As

Publication number Publication date
AU6045594A (en) 1994-09-26
US5698561A (en) 1997-12-16
JPH08507514A (ja) 1996-08-13
EP0688216A1 (en) 1995-12-27
HU9402578D0 (en) 1994-11-28
US5607938A (en) 1997-03-04
WO1994020102A2 (en) 1994-09-15
KR960700711A (ko) 1996-02-24
CN1118990A (zh) 1996-03-20
US5866598A (en) 1999-02-02
HUT68293A (en) 1995-06-28
WO1994020102A3 (en) 1994-10-27
AU683447B2 (en) 1997-11-13
TW305760B (enExample) 1997-05-21

Similar Documents

Publication Publication Date Title
US4663318A (en) Method of treating Alzheimer's disease
EP0543015B1 (en) Composition, method and kit for potentiating antitumor activity and for curing tumor
JPH0555484B2 (enExample)
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
JPWO1992021345A1 (ja) 抗腫瘍効果増強のための及び腫瘍治療のための組成物
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
US5607938A (en) Medicament for treating or preventing cerebrovascular infarction
JP2002537255A (ja) リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
EP0924985A1 (en) Method for inhibiting the expression of fas
JPWO2002092096A1 (ja) 抗腫瘍剤
JPH11503721A (ja) ベンズアミド誘導体の新規用途
JP2003503353A (ja) 冠状動脈移植片血管攣縮の治療または予防方法
CA2431125C (en) A method for treating erectile dysfunction
JPH1135464A (ja) ３−アルコキシピリジン誘導体の血管内膜肥厚の予防または治療剤
JP3388775B2 (ja) 脳障害改善剤
JP3845307B2 (ja) 心筋梗塞治療薬
JP2003267871A (ja) 放射線障害予防剤
JPH0881374A (ja) 皮膚そう痒症の予防または治療薬
WO2003041704A1 (fr) Agent preventif ou remede destine au prurit
JPS6137785A (ja) キサンチン誘導体とｏ―アセチルサリチル酸からなる血液成分障害起因疾患治療剤
WO1985003866A1 (fr) Agents de traitement d'immunodeficience, leur procede de traite ment et leur utilisation
NZ243833A (en) Pharmaceutical use of substituted exo or endo hydrogenated 2,6-methano-2h-quinolizine derivatives for producing an orexigenic effect in a patient
GB2319961A (en) Pharmaceutical composition for treatment of restenosis
JP2005041801A (ja) 細胞移植療法後の予後改善剤
JPH07309752A (ja) 免疫抑制剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead